SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Kilitch Drugs India informs about closure of trading window

27 Dec 2025 Evaluate

Kilitch Drugs India has informed that trading window will be closed with effect from 1st January 2026 till expiry of 48 hours from the declaration of unaudited financial results of the company for the quarter ended 31st December, 2025.

The above information is a part of company’s filings submitted to BSE.


Kilitch Drugs(India) Share Price

128.35 -4.30 (-3.24%)
10-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1654.70
Dr. Reddys Lab 1232.00
Cipla 1229.60
Zydus Lifesciences 915.45
Lupin 2332.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×